Genomics in Drug Discovery and Development (Training Workshop)

Explore how genomics information and data collection is driving change within drug development. This training workshop is aimed at early career pre-clinical scientists and early career clinical development professionals.

Save up to 24% with our early bird offer - ends 9 February 2023.

Tickets

Member Registration	Non-Member Ticket	£145.00
Non-Member Registration	Non-Member Ticket	£195.00

This online training workshop will explore how genomics information and data collection is driving change within drug development. This training course is aimed at early career pre-clinical scientists and early career clinical development professionals and will help them understand the relevance of genomics within the drug development process.

Learning Outcomes:
1. How targeted approaches and applications in early drug discovery are changing because of genomic data
2. The continued growth of bioinformation and managing big data
3. Understanding the role of consent forms and considerations for a fuller data collection from patients
4. The importance of diagnostics and the need for better markers within in clinic

If you have any questions, please do not hesitate to contact the Education team (education@bps.ac.uk / +44 20 7239 0170).

View and download a copy of the programme

10:00 - 10:15 Welcome and plan for the day
Caroline Haefliger - Head of Translational Medicine, Debiopharm

10:15 - 10:45 Genomics sample collections - ethics and consent
Helen Stevens - Principal Scientist, Centre for Genomics Research AstraZeneca

10:45 - 11:15 Towards two million genomes - overcoming challenges of data volume
Stewart MacArthur - Director of Genome Informatics, AstraZeneca

11:15 - 11:45 How genetic information is transforming drug discovery
Richard Turner - Director in Genomic Sciences and Head of Pharmacogenetics, GSK

11:45 - 12:00 Break

12:00 - 12:30 Precision medicine in the clinic
Caroline Haefliger - Head of Translational Medicine, Debiopharm

12:30 - 13:00 Breakout session 1

13:00 - 13:40 Lunch

13:40 - 14:10 Breakout session 2

14:10 - 14:40 UK Biobank sequencing data informs target identification
Jonathan Mitchell - Genome Analyst, AstraZeneca

14:40 - 15:10 Breakout session 3

15:10 - 15:25 Break

15:25 - 15:55 The Industry Pharmacogenomics Working Group (I-PWG) - Overcoming challenges in pharmacogenomics together
Julian Arbuckle - Director of the Industry Pharmacogenomics Working Group (I-PWG)

15:55 - 16:25 Breakout session 4

16:25 - 16:30 Summary and revisit Learning Outcomes
Caroline Haefliger - Head of Translational Medicine, Debiopharm

Speaker Biographies

Caroline Haefliger

Carolina Haefliger is a physician and clinical geneticist by training. Carolina is currently the Head of Translational Medicine at Debiopharm International, based in Lausanne, Switzerland. Having worked in the Biotech and Pharma industries for more that 19 years.
Carolina has experience of working with biomarkers, genomics, and precision medicine as well as translational medicine in the areas of oncology, cardiovascular, metabolism, and kidney disease.

Helen Stevens

Helen is a Principle Scientist at the Centre for Genomics at AstraZeneca. Her role is to advise study teams, ethics committees and biobanks from AstraZeneca and major collaborations, to enable sample collections and analysis of up to two million genomes.
Driving inclusion of broad, scientific, health related pharmacogenomics within clinical trails in an ethical and compliant way. Enthusiastic about generating sustainable, usable genomics cohorts, from consent through to biobanking and associated responsible use of data. Transforming drug development through genomics. Follows the dynamic horizon of country regulations regarding collection and use of genomic samples and derived data.

Stewart MacArthur

Stewart MacArthur is a Director if Bioinformatics at AstraZeneca. His role involves overseeing the delivery of informatics solutions for the two millions genomes project.

Richard Turner

Richard Turner is a director in Genomic Sciences and Head of Pharmacogenetics at GSK. He studied medicine at the University of Cambridge and completed clinical training in Clinical Pharmacology and Therapeutics with General Internal Medicine in Liverpool. Prior to joining GSK, he held an Academic Clinical Lectureship and a Health Education England Genomics Research Fellowship.

Jonathan Mitchell

Jonathan Mitchell joined AstraZeneca as an analyst in the Centre for Genomics Research (CGR) in 2021 from Genomics England where he worked as part of the team developing the pipeline to bring whole genome sequencing testing to cancer patients in the NHS. As an analyst at the CGR, Jonathan uses large scale population genomic datasets to identify and validate drug targets, and inform precision medicine strategies.

Speaker Biographies

From

23 March 2023

Time

10am GMT to 4.30pm GMT

Venue

Online